SlideShare uma empresa Scribd logo
1 de 49
Baixar para ler offline
Retinopathy of
prematurity
Bipin Bista
Resident
Ophthalmology
NMCTH, Birgunj
Definition :
• Retinopathy of prematurity (ROP) is a
proliferative retinopathy affecting premature
infants of very low birth weight, who have
often been exposed to high ambient oxygen
concentrations.
Schematic diagram for vessels
development
History
• Identified by Terry in 1942 , where he first told
regarding retrolental fibroplasia.
• Later Owens and Owens found out that hyaloid
system are normal at the time of birth and
retrolental fibroplasia developed post-natally.
• Term coined by Heath in 1951.
• In late 60s and 70s, ABG analysis came into use, this
evolved the paediatrician to titrate the incubator
oxygen.
Role of Oxygen
• In 1950s, confirmation were brought regarding
oxygen being the major cause.
• Later on, on different experimental findings :
― factors associated with very low birth weight (Lucey
and dangman).
―Cyanotic heart disease and ROP (Kalina et al and
Johns et al)
• Supplemental Therapeutic Oxygen for Prethreshold
ROP (STOP-ROP) trial.
Mechanism of Oxygen’s effect in immature
retina
 Primary Stage : Retinal vasoconstriction and
vascular occlusion
• Vascular caliber decreases by 50% but may rebound to its
original dimensions.
• May be sustained vasoconstriction if there’s elevated arterial
oxygen pressure.
• Local vascular obliteration is completed by 2-3 days of
sustained hyperoxic environment.
 Secondary stage :Retinal neovascularization
• Marked endothelial proliferation from residual vascular
complexes, immediately adjacent to ablated retinal capillaries
during hyperoxia.
• New vessels are formed & erupt from Internal Limiting
Membrane.
• Newly formed angioblastic mass called as popcorn formation,
mature into neovascular formation which are filled with
pericytes.
• Remodelling : regress from areas of higher oxygen and grows
towards area of lower oxygen.
Pathogenesis
• Mesenchyme, blood vessel precursor, grows from optic disc
through nerve fiber of retina. On posterior edge of advancing
mesenchyme, a “chicken wire” meshwork of capillaries
develops to produce mature arteries and veins. (Ashton)
• Similarly Vascular endothelial growth factor (VEGF)key factor
for vessels growth was stated as Factor X. (Michaelson)
• According to Foos, he divided into Vanguard and Rearguard.
Vanguard –anterior compartment containing spindle cells
(progenitors)- Garner for nourishment.
Rearguard contains primitive endothelial cells which aggregates
into cords for neovascularization.
Flynn and co-workers
1. Injury occurs where it has differentiated from mesenchyme
to form primitive capillary meshwork.
2. After injury, mature vessels merge and survive via few
vascular channels and forms mesenchymal AV shunts that
replaces destroyed capillary bed.
3. Shunt (AP-AV) consists of a nest of primitive mesenchymal &
maturing endothelial cells ,fed by mature arteries and veins.
Flynn also stated :-
• Retina will remain in dormant period after injury for
days to months
• Fate of the eye is decided as the tissue thickens and
changes its colour.
Grey white > pink > salmon > red.
• In Progressive disease, primitive cells proliferate.
• Normally, these cells divide and differentiate to form
normal capillary endothelium.
International Classification
• The International Classification of ROP (ICROP)
that was published in 1984 standardized the
terminology used to describe ROP .In 2005, a
second committee for the classification of ROP
revised the original ICROP.
Staging of ROP
• 5 stages :
1. Demarcation line
2. Ridge
3. Ridge with extraretinal fibrovascular proliferation
4. Subtotal Retinal Detachment (RD)
―4a : Extrafoveal RD
―4b : Partial RD with fovea
5. Total RD
Stage 1 : Demarcation Line
• Line separating Ant. &
Post. Retina
• Usually white & flat ,
lies within plane of
retina
• Due to abnormal
branching or arcading
of vessels.
Stage 2 : Ridge
• Grown demarcation line
• Has height & width &
occupies volume
• Extends centripetally
within the globe
• Small tufts of new
vessels (“popcorn “
lesion) seen posterior
but not attached to
ridge.
Stage 3:Ridge with extraretinal
fibrovascular proliferation
• Localised continuous
with posterior & inferior
aspect, causing ragged
appearance of ridge as
proliferation increases.
• Presence of increased
retinal vessels coursing
from retinal surface ,not
only constitute RD but
also signify Vitreous
Traction.
Stage 4a : Subtotal Retinal Detachment
(Extrafoveal)
• concave, tractional type
• Occurs in periphery
without central macula
• Located at proliferative
areas.
• May extend 360
degrees without
including macula
• Prognosis : good if
anterior.
Stage 4b : Partial Retinal detachment
with foveal involvement.
• Involves fovea
• Prognosis : poor
Stage 5 : Total Retinal Detachment
• Usually funnel shaped
as seen in USG.
• Involves both anterior
and posterior part.
• Concave configuration
and extends upto optic
disc.
Plus Disease
• More florid form of ROP
• Increased dilatation &
tortuosity of retinal
vessels
• Iris vascular
engorgement.
• Pupillary rigidity
• Vitreous haze
• + : key sign of worst
prognosis.
Preplus disease/(‘rush’) disease
• Uncommon but if
untreated reaches to
stage 5 within few days
• Posterior location
• Prominence of plus
disease
• Ill-defined nature of
retinopathy.
Other factors
1. Appearance of retrolenticular space
2. Peripheral trough : presence of peripheral
red reflex in combination with apparent
narrow funnel shows avascular peripheral
retina. ( stage 5)
3. Anterior segment abnormalities ( stage 4 or
5).
Prethreshold and threshold disease
• Prethreshold ROP, Type 1.
› Zone I, any stage with plus disease;
› zone I, stage 3 without plus disease;
› zone II, stage 2 or 3 with plus disease.
• Prethreshold ROP, Type 2.
› Zone I, stage 1 or 2 without plus disease;
› zone II, stage 3 without plus disease.
• Threshold ROP.
› Zone I or II, stage 3 (five contiguous or eight total
clock hours with plus disease).
Involution of ROP
• Typically at 38-39 weeks post-conceptual or
post-menstrual
• Downgrading of staging &/or growth of
retinal vessels into more peripheral zone
• Present in 70-80 % .
Cicatricial Disease
• About 20% of infants with active ROP may
develop this complication.
• More general and more advanced or more
posterior the proliferation , worse the
sequelae.
• Temporal vitreoretinal fibrosis and
straightening of vascular arcades with
‘dragging’ of macula and disc .
Cicatricial disease (continue)
• Progress to retrolental fibrovascular tissue
lead to falciform retinal fold formation and to
retinal detachment, sometimes total and
called as retrolental fibroplasia.
• Secondary glaucoma (angle closure) : major
challenge.
Differential Diagnosis
Stage 1 to 3
• Familial exudative
vitreoretinopathy (FEVR)
(chief consideration)
• Coats disease
• Eales disease
• retinoschisis
Stage 4 & 5
• Retinoblastoma
• Persistent fetal vasculature
• Congenital cataract
• Incontinentia pigmenti -XD
• FEVR -AD
• Norrie’s disease -XR
Risk Factors
• Cyanosis
• Apnea
• Mechanical ventilation
• Intraventricular
Hemorrhage
• Seizures
• Transfusions
• Septicaemia
• In utero hypoxia
• Anemia
• Patent ductus
arteriosus
• Vitamin E Deficiency
• High Myopic
Screening Guidelines
• every infant ≤306/7 weeks’ GA regardless of
birth weight, as well as any infant with a birth
weight ≤1250 g were screened.
• In 2014, an updated (2009 to 2014) literature
search was conducted.
Screening Guidelines
• 1st examination should be considered 4-6
weeks from birth i.e., 31 to 33 weeks post-
conception.
• Prior to 4 weeks are not considered necessary.
Techniques of eye examination
• Effective dilatation (
cyclopentolate 0.2%
and phenylephrine 1%)
twice 1 to 5 minutes
apart.
• Lid speculum :
Cook,Alfanso,Sauer &
Schaefer spatula
• Restrain
• N-P cultural swab
• Scleral depression
Prophylaxis & Therapy
1. Vitamin E : Recognized antioxidant of choice .
shouldn’t exceed 3 mg/dl.
(hittner et al and kretzer et al).
Role of Light
• On various researches and trials, no effective
results have been found.
• Neither the American Academy of
Ophthalmology nor the American Academy of
Pediatrics have made any recommendations
about restricting ambient light from the eyes
of premature infants.
Management
• Laser > cryotherapy : easier
and few post-op sequalae.
• Diode laser (810 nm) is
better than argon laser (488-
532 nm ).
• Photocoagulation burns are
distributed 0.5-1 burn width
apart .
• 600-1000 laser spots.
• Power : 0.15 watts
• Pulse duration : 0.3-0.4
seconds.
Management (continue)
• Chest & CVS
examination
• Swaddled in blanket
with mydriatics &
anaesthesia.
• In case of GA, perform
laser in both the eyes.
Intravitreal anti- VEGF agents
• More precedence in
zone I
• Look after systemic
complications and long
term effects.
• The Bevacizumab Eliminates the
Angiogenic Threat of Retinopathy
of Prematurity (BEAT-ROP) Study
Lens-sparing vitrectomy
• Can be performed for stage 4a , where success
rate is 90 % .
Early treatment of ROP (ETROP) Trial
2003
Type 1 ROP
• ZONE II : plus disease with
stage 2 or 3.
• ZONE I :Plus disease with stage
1, 2 or 3.
• Stage 3 without Plus disease.
• Treatment : Peripheral laser
ablation.
• Plus disease: involve at least 2
quadrants of fundus with
floridity.
Type 2 ROP
• Zone II : Stage 3 without
plus disease.
• Zone I : Stage 1 or 2 without
plus disease.
• Treatment : Wait and watch
for progression.
Other recent studies
• IGF-1 pathway & dietary supplementation
with omega-3 polyunsaturated fatty acids
(PUFAs).
• Recombinant Erythropoeitin (Epo)
Associated conditions & late sequalae
• Myopia with astigmatism
• Anisometropia
• Strabismus
• Amblyopia
• Cataract
• Glaucoma
• Macular pigment epitheliopathy
• VR scarring
• TRD
• Anomalous foveal changes.
TELE-ROP
• Digital photographic retinal images that are
captured and sent for remote interpretation is
a developing approach to ROP screening
Evaluating Acute-phase ROP (e-ROP) study
References
1. Retina , 4th edition , Stephen J. Ryan
2. Kanski’s clinical ophthalmology , 8th edition,
Brad bowling.
3. Jefferies, A. L., & Canadian Paediatric Society,
Fetus and Newborn Committee. (2016).
Retinopathy of prematurity: An update on
screening and management. Paediatrics &
Child Health, 21(2), 101–104.
THANK YOU

Mais conteúdo relacionado

Mais procurados

Congenital infantile esotropia
Congenital infantile esotropiaCongenital infantile esotropia
Congenital infantile esotropiaOm Patel
 
Posterior capsular opacification
Posterior capsular opacificationPosterior capsular opacification
Posterior capsular opacificationAshish Chaudhari
 
Rhegmatogenous retinal detachment
Rhegmatogenous retinal detachmentRhegmatogenous retinal detachment
Rhegmatogenous retinal detachmentSamuel Ponraj
 
Fundus Fluoroscein Angiography
Fundus Fluoroscein AngiographyFundus Fluoroscein Angiography
Fundus Fluoroscein AngiographyRashmi Ranjan
 
Posterior vitreous detachment (PVD)
Posterior vitreous detachment (PVD)Posterior vitreous detachment (PVD)
Posterior vitreous detachment (PVD)Md Riyaj Ali
 
retinopathy of prematurity
retinopathy of prematurityretinopathy of prematurity
retinopathy of prematurityRohit Rao
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurityBarun Garg
 
Management of diabetic retinopathy
Management of diabetic retinopathyManagement of diabetic retinopathy
Management of diabetic retinopathyBipin Bista
 
Management of retinal detachment
Management of retinal detachmentManagement of retinal detachment
Management of retinal detachmentAmreen Deshmukh
 
FUNDUS FLUORESCEIN ANGIOGRAPHY
FUNDUS FLUORESCEIN ANGIOGRAPHYFUNDUS FLUORESCEIN ANGIOGRAPHY
FUNDUS FLUORESCEIN ANGIOGRAPHYAnuraag Singh
 

Mais procurados (20)

Congenital infantile esotropia
Congenital infantile esotropiaCongenital infantile esotropia
Congenital infantile esotropia
 
Posterior capsular opacification
Posterior capsular opacificationPosterior capsular opacification
Posterior capsular opacification
 
Rhegmatogenous retinal detachment
Rhegmatogenous retinal detachmentRhegmatogenous retinal detachment
Rhegmatogenous retinal detachment
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
Corneal Dystrophies
Corneal DystrophiesCorneal Dystrophies
Corneal Dystrophies
 
Fundus Fluoroscein Angiography
Fundus Fluoroscein AngiographyFundus Fluoroscein Angiography
Fundus Fluoroscein Angiography
 
Posterior vitreous detachment (PVD)
Posterior vitreous detachment (PVD)Posterior vitreous detachment (PVD)
Posterior vitreous detachment (PVD)
 
RHEGMATOGENOUS Retinal detachment
 RHEGMATOGENOUS Retinal detachment RHEGMATOGENOUS Retinal detachment
RHEGMATOGENOUS Retinal detachment
 
retinopathy of prematurity
retinopathy of prematurityretinopathy of prematurity
retinopathy of prematurity
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
Management of diabetic retinopathy
Management of diabetic retinopathyManagement of diabetic retinopathy
Management of diabetic retinopathy
 
Retinopathy of prematurity (upload for site)
Retinopathy of prematurity (upload for site)Retinopathy of prematurity (upload for site)
Retinopathy of prematurity (upload for site)
 
Management of retinal detachment
Management of retinal detachmentManagement of retinal detachment
Management of retinal detachment
 
Rop seminar
Rop seminarRop seminar
Rop seminar
 
Pathological Myopia
Pathological MyopiaPathological Myopia
Pathological Myopia
 
Rop
RopRop
Rop
 
FUNDUS FLUORESCEIN ANGIOGRAPHY
FUNDUS FLUORESCEIN ANGIOGRAPHYFUNDUS FLUORESCEIN ANGIOGRAPHY
FUNDUS FLUORESCEIN ANGIOGRAPHY
 
Diabetic macular edema 2011 (1)
Diabetic macular edema 2011 (1)Diabetic macular edema 2011 (1)
Diabetic macular edema 2011 (1)
 
Cover tests
Cover testsCover tests
Cover tests
 

Semelhante a Retinopathy of prematurity

Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurityAnisha Rathod
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurityerameshita
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurityPavanShroff
 
DR WANI'S TALK ON Retinopathy of prematurity
DR WANI'S TALK ON Retinopathy of prematurity DR WANI'S TALK ON Retinopathy of prematurity
DR WANI'S TALK ON Retinopathy of prematurity vbwani
 
Retinopathy of prematurity vpr.pptx
Retinopathy of prematurity vpr.pptxRetinopathy of prematurity vpr.pptx
Retinopathy of prematurity vpr.pptxVishnu645963
 
APROP TREATMENT WITH LUCENTIS AND LASER
APROP TREATMENT WITH LUCENTIS AND LASERAPROP TREATMENT WITH LUCENTIS AND LASER
APROP TREATMENT WITH LUCENTIS AND LASERAjayDudani1
 
APROP TREATMENT
APROP TREATMENT APROP TREATMENT
APROP TREATMENT AjayDudani1
 
RETINOPATHY OF PREMATURITY
RETINOPATHY OF PREMATURITYRETINOPATHY OF PREMATURITY
RETINOPATHY OF PREMATURITYFaisal Anwar
 
Retinopathy of Prematurity.pptx
Retinopathy of Prematurity.pptxRetinopathy of Prematurity.pptx
Retinopathy of Prematurity.pptxSanikagurav1
 
Retinopathy Of Prematurity
Retinopathy Of PrematurityRetinopathy Of Prematurity
Retinopathy Of Prematuritylikuta
 
RETINOPATHY OF PREMATURITY
RETINOPATHY OF PREMATURITYRETINOPATHY OF PREMATURITY
RETINOPATHY OF PREMATURITYDrhunny88
 
Evaluation of White Pupillary Reflex FINAL.pptx
Evaluation of White Pupillary Reflex FINAL.pptxEvaluation of White Pupillary Reflex FINAL.pptx
Evaluation of White Pupillary Reflex FINAL.pptxMahfuz Shohag
 
Retinopathy of Primaturity
Retinopathy of PrimaturityRetinopathy of Primaturity
Retinopathy of PrimaturityKhulesh Sahu
 
RETINOPATHY OF PREMATURITY
RETINOPATHY OF PREMATURITY RETINOPATHY OF PREMATURITY
RETINOPATHY OF PREMATURITY MEDICS india
 

Semelhante a Retinopathy of prematurity (20)

Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
ROP_Dr. Pradeep Bastola.pptx
ROP_Dr. Pradeep Bastola.pptxROP_Dr. Pradeep Bastola.pptx
ROP_Dr. Pradeep Bastola.pptx
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
rop.pptx
rop.pptxrop.pptx
rop.pptx
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
Retinopathy of prematurity 2014 july 11
Retinopathy of prematurity 2014 july 11Retinopathy of prematurity 2014 july 11
Retinopathy of prematurity 2014 july 11
 
DR WANI'S TALK ON Retinopathy of prematurity
DR WANI'S TALK ON Retinopathy of prematurity DR WANI'S TALK ON Retinopathy of prematurity
DR WANI'S TALK ON Retinopathy of prematurity
 
Retinopathy of prematurity vpr.pptx
Retinopathy of prematurity vpr.pptxRetinopathy of prematurity vpr.pptx
Retinopathy of prematurity vpr.pptx
 
APROP TREATMENT WITH LUCENTIS AND LASER
APROP TREATMENT WITH LUCENTIS AND LASERAPROP TREATMENT WITH LUCENTIS AND LASER
APROP TREATMENT WITH LUCENTIS AND LASER
 
APROP TREATMENT
APROP TREATMENT APROP TREATMENT
APROP TREATMENT
 
RETINOPATHY OF PREMATURITY
RETINOPATHY OF PREMATURITYRETINOPATHY OF PREMATURITY
RETINOPATHY OF PREMATURITY
 
ROP.pptx
ROP.pptxROP.pptx
ROP.pptx
 
Retinopathy of Prematurity.pptx
Retinopathy of Prematurity.pptxRetinopathy of Prematurity.pptx
Retinopathy of Prematurity.pptx
 
Retinopathy Of Prematurity
Retinopathy Of PrematurityRetinopathy Of Prematurity
Retinopathy Of Prematurity
 
RETINOPATHY OF PREMATURITY
RETINOPATHY OF PREMATURITYRETINOPATHY OF PREMATURITY
RETINOPATHY OF PREMATURITY
 
Evaluation of White Pupillary Reflex FINAL.pptx
Evaluation of White Pupillary Reflex FINAL.pptxEvaluation of White Pupillary Reflex FINAL.pptx
Evaluation of White Pupillary Reflex FINAL.pptx
 
Retinopathy of Primaturity
Retinopathy of PrimaturityRetinopathy of Primaturity
Retinopathy of Primaturity
 
RETINOPATHY OF PREMATURITY
RETINOPATHY OF PREMATURITY RETINOPATHY OF PREMATURITY
RETINOPATHY OF PREMATURITY
 

Mais de Bipin Bista

Ocular therapeutics
Ocular therapeutics Ocular therapeutics
Ocular therapeutics Bipin Bista
 
Diseases of the orbit
Diseases of the orbitDiseases of the orbit
Diseases of the orbitBipin Bista
 
Approach to orbital surgery.
Approach to orbital surgery.Approach to orbital surgery.
Approach to orbital surgery.Bipin Bista
 
Acquired anomalies of lacrimal system
Acquired anomalies of lacrimal systemAcquired anomalies of lacrimal system
Acquired anomalies of lacrimal systemBipin Bista
 
Orbital neoplasms & malformations
Orbital neoplasms & malformationsOrbital neoplasms & malformations
Orbital neoplasms & malformationsBipin Bista
 
Ophthalmic viscosurgical devices
Ophthalmic viscosurgical devicesOphthalmic viscosurgical devices
Ophthalmic viscosurgical devicesBipin Bista
 
Iol power calculation (adult & paediatric)
Iol power calculation (adult & paediatric)Iol power calculation (adult & paediatric)
Iol power calculation (adult & paediatric)Bipin Bista
 
Indications & techniques of lens surgery
Indications & techniques of lens surgeryIndications & techniques of lens surgery
Indications & techniques of lens surgeryBipin Bista
 
Evolution, types, materials of iol
Evolution, types, materials of iolEvolution, types, materials of iol
Evolution, types, materials of iolBipin Bista
 
Cataract extraction (manual) and cataract surgery
Cataract extraction (manual) and cataract surgeryCataract extraction (manual) and cataract surgery
Cataract extraction (manual) and cataract surgeryBipin Bista
 
Biochemistry and biophysics of lens
Biochemistry and biophysics of lensBiochemistry and biophysics of lens
Biochemistry and biophysics of lensBipin Bista
 
Anatomy and physiology of lens
Anatomy and physiology of lensAnatomy and physiology of lens
Anatomy and physiology of lensBipin Bista
 
Anaesthesia for cataract surgery
Anaesthesia for cataract surgeryAnaesthesia for cataract surgery
Anaesthesia for cataract surgeryBipin Bista
 
Age related changes of lens
Age related changes of lensAge related changes of lens
Age related changes of lensBipin Bista
 
Vogt koyanagi-harada disease
Vogt koyanagi-harada diseaseVogt koyanagi-harada disease
Vogt koyanagi-harada diseaseBipin Bista
 
Tubercular uveitis
Tubercular uveitisTubercular uveitis
Tubercular uveitisBipin Bista
 
Spirochetal disease syphilis
Spirochetal disease  syphilisSpirochetal disease  syphilis
Spirochetal disease syphilisBipin Bista
 
Sarcoidotic uveitis
Sarcoidotic uveitisSarcoidotic uveitis
Sarcoidotic uveitisBipin Bista
 
Posterior uveitis of unknown cause white spot syndromes
Posterior uveitis of unknown cause white spot syndromesPosterior uveitis of unknown cause white spot syndromes
Posterior uveitis of unknown cause white spot syndromesBipin Bista
 
Ocular toxoplasmosis
Ocular toxoplasmosisOcular toxoplasmosis
Ocular toxoplasmosisBipin Bista
 

Mais de Bipin Bista (20)

Ocular therapeutics
Ocular therapeutics Ocular therapeutics
Ocular therapeutics
 
Diseases of the orbit
Diseases of the orbitDiseases of the orbit
Diseases of the orbit
 
Approach to orbital surgery.
Approach to orbital surgery.Approach to orbital surgery.
Approach to orbital surgery.
 
Acquired anomalies of lacrimal system
Acquired anomalies of lacrimal systemAcquired anomalies of lacrimal system
Acquired anomalies of lacrimal system
 
Orbital neoplasms & malformations
Orbital neoplasms & malformationsOrbital neoplasms & malformations
Orbital neoplasms & malformations
 
Ophthalmic viscosurgical devices
Ophthalmic viscosurgical devicesOphthalmic viscosurgical devices
Ophthalmic viscosurgical devices
 
Iol power calculation (adult & paediatric)
Iol power calculation (adult & paediatric)Iol power calculation (adult & paediatric)
Iol power calculation (adult & paediatric)
 
Indications & techniques of lens surgery
Indications & techniques of lens surgeryIndications & techniques of lens surgery
Indications & techniques of lens surgery
 
Evolution, types, materials of iol
Evolution, types, materials of iolEvolution, types, materials of iol
Evolution, types, materials of iol
 
Cataract extraction (manual) and cataract surgery
Cataract extraction (manual) and cataract surgeryCataract extraction (manual) and cataract surgery
Cataract extraction (manual) and cataract surgery
 
Biochemistry and biophysics of lens
Biochemistry and biophysics of lensBiochemistry and biophysics of lens
Biochemistry and biophysics of lens
 
Anatomy and physiology of lens
Anatomy and physiology of lensAnatomy and physiology of lens
Anatomy and physiology of lens
 
Anaesthesia for cataract surgery
Anaesthesia for cataract surgeryAnaesthesia for cataract surgery
Anaesthesia for cataract surgery
 
Age related changes of lens
Age related changes of lensAge related changes of lens
Age related changes of lens
 
Vogt koyanagi-harada disease
Vogt koyanagi-harada diseaseVogt koyanagi-harada disease
Vogt koyanagi-harada disease
 
Tubercular uveitis
Tubercular uveitisTubercular uveitis
Tubercular uveitis
 
Spirochetal disease syphilis
Spirochetal disease  syphilisSpirochetal disease  syphilis
Spirochetal disease syphilis
 
Sarcoidotic uveitis
Sarcoidotic uveitisSarcoidotic uveitis
Sarcoidotic uveitis
 
Posterior uveitis of unknown cause white spot syndromes
Posterior uveitis of unknown cause white spot syndromesPosterior uveitis of unknown cause white spot syndromes
Posterior uveitis of unknown cause white spot syndromes
 
Ocular toxoplasmosis
Ocular toxoplasmosisOcular toxoplasmosis
Ocular toxoplasmosis
 

Último

Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledgeassessoriafabianodea
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalityhardikdabas3
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 

Último (20)

Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortality
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 

Retinopathy of prematurity

  • 2. Definition : • Retinopathy of prematurity (ROP) is a proliferative retinopathy affecting premature infants of very low birth weight, who have often been exposed to high ambient oxygen concentrations.
  • 3. Schematic diagram for vessels development
  • 4. History • Identified by Terry in 1942 , where he first told regarding retrolental fibroplasia. • Later Owens and Owens found out that hyaloid system are normal at the time of birth and retrolental fibroplasia developed post-natally. • Term coined by Heath in 1951. • In late 60s and 70s, ABG analysis came into use, this evolved the paediatrician to titrate the incubator oxygen.
  • 5. Role of Oxygen • In 1950s, confirmation were brought regarding oxygen being the major cause. • Later on, on different experimental findings : ― factors associated with very low birth weight (Lucey and dangman). ―Cyanotic heart disease and ROP (Kalina et al and Johns et al) • Supplemental Therapeutic Oxygen for Prethreshold ROP (STOP-ROP) trial.
  • 6. Mechanism of Oxygen’s effect in immature retina  Primary Stage : Retinal vasoconstriction and vascular occlusion • Vascular caliber decreases by 50% but may rebound to its original dimensions. • May be sustained vasoconstriction if there’s elevated arterial oxygen pressure. • Local vascular obliteration is completed by 2-3 days of sustained hyperoxic environment.
  • 7.  Secondary stage :Retinal neovascularization • Marked endothelial proliferation from residual vascular complexes, immediately adjacent to ablated retinal capillaries during hyperoxia. • New vessels are formed & erupt from Internal Limiting Membrane. • Newly formed angioblastic mass called as popcorn formation, mature into neovascular formation which are filled with pericytes. • Remodelling : regress from areas of higher oxygen and grows towards area of lower oxygen.
  • 8.
  • 9.
  • 10. Pathogenesis • Mesenchyme, blood vessel precursor, grows from optic disc through nerve fiber of retina. On posterior edge of advancing mesenchyme, a “chicken wire” meshwork of capillaries develops to produce mature arteries and veins. (Ashton) • Similarly Vascular endothelial growth factor (VEGF)key factor for vessels growth was stated as Factor X. (Michaelson) • According to Foos, he divided into Vanguard and Rearguard. Vanguard –anterior compartment containing spindle cells (progenitors)- Garner for nourishment. Rearguard contains primitive endothelial cells which aggregates into cords for neovascularization.
  • 11.
  • 12. Flynn and co-workers 1. Injury occurs where it has differentiated from mesenchyme to form primitive capillary meshwork. 2. After injury, mature vessels merge and survive via few vascular channels and forms mesenchymal AV shunts that replaces destroyed capillary bed. 3. Shunt (AP-AV) consists of a nest of primitive mesenchymal & maturing endothelial cells ,fed by mature arteries and veins.
  • 13. Flynn also stated :- • Retina will remain in dormant period after injury for days to months • Fate of the eye is decided as the tissue thickens and changes its colour. Grey white > pink > salmon > red. • In Progressive disease, primitive cells proliferate. • Normally, these cells divide and differentiate to form normal capillary endothelium.
  • 14. International Classification • The International Classification of ROP (ICROP) that was published in 1984 standardized the terminology used to describe ROP .In 2005, a second committee for the classification of ROP revised the original ICROP.
  • 15.
  • 16. Staging of ROP • 5 stages : 1. Demarcation line 2. Ridge 3. Ridge with extraretinal fibrovascular proliferation 4. Subtotal Retinal Detachment (RD) ―4a : Extrafoveal RD ―4b : Partial RD with fovea 5. Total RD
  • 17. Stage 1 : Demarcation Line • Line separating Ant. & Post. Retina • Usually white & flat , lies within plane of retina • Due to abnormal branching or arcading of vessels.
  • 18. Stage 2 : Ridge • Grown demarcation line • Has height & width & occupies volume • Extends centripetally within the globe • Small tufts of new vessels (“popcorn “ lesion) seen posterior but not attached to ridge.
  • 19. Stage 3:Ridge with extraretinal fibrovascular proliferation • Localised continuous with posterior & inferior aspect, causing ragged appearance of ridge as proliferation increases. • Presence of increased retinal vessels coursing from retinal surface ,not only constitute RD but also signify Vitreous Traction.
  • 20. Stage 4a : Subtotal Retinal Detachment (Extrafoveal) • concave, tractional type • Occurs in periphery without central macula • Located at proliferative areas. • May extend 360 degrees without including macula • Prognosis : good if anterior.
  • 21. Stage 4b : Partial Retinal detachment with foveal involvement. • Involves fovea • Prognosis : poor
  • 22. Stage 5 : Total Retinal Detachment • Usually funnel shaped as seen in USG. • Involves both anterior and posterior part. • Concave configuration and extends upto optic disc.
  • 23. Plus Disease • More florid form of ROP • Increased dilatation & tortuosity of retinal vessels • Iris vascular engorgement. • Pupillary rigidity • Vitreous haze • + : key sign of worst prognosis.
  • 24. Preplus disease/(‘rush’) disease • Uncommon but if untreated reaches to stage 5 within few days • Posterior location • Prominence of plus disease • Ill-defined nature of retinopathy.
  • 25. Other factors 1. Appearance of retrolenticular space 2. Peripheral trough : presence of peripheral red reflex in combination with apparent narrow funnel shows avascular peripheral retina. ( stage 5) 3. Anterior segment abnormalities ( stage 4 or 5).
  • 26. Prethreshold and threshold disease • Prethreshold ROP, Type 1. › Zone I, any stage with plus disease; › zone I, stage 3 without plus disease; › zone II, stage 2 or 3 with plus disease. • Prethreshold ROP, Type 2. › Zone I, stage 1 or 2 without plus disease; › zone II, stage 3 without plus disease. • Threshold ROP. › Zone I or II, stage 3 (five contiguous or eight total clock hours with plus disease).
  • 27. Involution of ROP • Typically at 38-39 weeks post-conceptual or post-menstrual • Downgrading of staging &/or growth of retinal vessels into more peripheral zone • Present in 70-80 % .
  • 28. Cicatricial Disease • About 20% of infants with active ROP may develop this complication. • More general and more advanced or more posterior the proliferation , worse the sequelae. • Temporal vitreoretinal fibrosis and straightening of vascular arcades with ‘dragging’ of macula and disc .
  • 29. Cicatricial disease (continue) • Progress to retrolental fibrovascular tissue lead to falciform retinal fold formation and to retinal detachment, sometimes total and called as retrolental fibroplasia. • Secondary glaucoma (angle closure) : major challenge.
  • 30. Differential Diagnosis Stage 1 to 3 • Familial exudative vitreoretinopathy (FEVR) (chief consideration) • Coats disease • Eales disease • retinoschisis Stage 4 & 5 • Retinoblastoma • Persistent fetal vasculature • Congenital cataract • Incontinentia pigmenti -XD • FEVR -AD • Norrie’s disease -XR
  • 31. Risk Factors • Cyanosis • Apnea • Mechanical ventilation • Intraventricular Hemorrhage • Seizures • Transfusions • Septicaemia • In utero hypoxia • Anemia • Patent ductus arteriosus • Vitamin E Deficiency • High Myopic
  • 32. Screening Guidelines • every infant ≤306/7 weeks’ GA regardless of birth weight, as well as any infant with a birth weight ≤1250 g were screened. • In 2014, an updated (2009 to 2014) literature search was conducted.
  • 33. Screening Guidelines • 1st examination should be considered 4-6 weeks from birth i.e., 31 to 33 weeks post- conception. • Prior to 4 weeks are not considered necessary.
  • 34.
  • 35.
  • 36.
  • 37. Techniques of eye examination • Effective dilatation ( cyclopentolate 0.2% and phenylephrine 1%) twice 1 to 5 minutes apart. • Lid speculum : Cook,Alfanso,Sauer & Schaefer spatula • Restrain • N-P cultural swab • Scleral depression
  • 38. Prophylaxis & Therapy 1. Vitamin E : Recognized antioxidant of choice . shouldn’t exceed 3 mg/dl. (hittner et al and kretzer et al).
  • 39. Role of Light • On various researches and trials, no effective results have been found. • Neither the American Academy of Ophthalmology nor the American Academy of Pediatrics have made any recommendations about restricting ambient light from the eyes of premature infants.
  • 40. Management • Laser > cryotherapy : easier and few post-op sequalae. • Diode laser (810 nm) is better than argon laser (488- 532 nm ). • Photocoagulation burns are distributed 0.5-1 burn width apart . • 600-1000 laser spots. • Power : 0.15 watts • Pulse duration : 0.3-0.4 seconds.
  • 41. Management (continue) • Chest & CVS examination • Swaddled in blanket with mydriatics & anaesthesia. • In case of GA, perform laser in both the eyes.
  • 42. Intravitreal anti- VEGF agents • More precedence in zone I • Look after systemic complications and long term effects. • The Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) Study
  • 43. Lens-sparing vitrectomy • Can be performed for stage 4a , where success rate is 90 % .
  • 44. Early treatment of ROP (ETROP) Trial 2003 Type 1 ROP • ZONE II : plus disease with stage 2 or 3. • ZONE I :Plus disease with stage 1, 2 or 3. • Stage 3 without Plus disease. • Treatment : Peripheral laser ablation. • Plus disease: involve at least 2 quadrants of fundus with floridity. Type 2 ROP • Zone II : Stage 3 without plus disease. • Zone I : Stage 1 or 2 without plus disease. • Treatment : Wait and watch for progression.
  • 45. Other recent studies • IGF-1 pathway & dietary supplementation with omega-3 polyunsaturated fatty acids (PUFAs). • Recombinant Erythropoeitin (Epo)
  • 46. Associated conditions & late sequalae • Myopia with astigmatism • Anisometropia • Strabismus • Amblyopia • Cataract • Glaucoma • Macular pigment epitheliopathy • VR scarring • TRD • Anomalous foveal changes.
  • 47. TELE-ROP • Digital photographic retinal images that are captured and sent for remote interpretation is a developing approach to ROP screening Evaluating Acute-phase ROP (e-ROP) study
  • 48. References 1. Retina , 4th edition , Stephen J. Ryan 2. Kanski’s clinical ophthalmology , 8th edition, Brad bowling. 3. Jefferies, A. L., & Canadian Paediatric Society, Fetus and Newborn Committee. (2016). Retinopathy of prematurity: An update on screening and management. Paediatrics & Child Health, 21(2), 101–104.

Notas do Editor

  1. 15 million preterm birth, India, china, Nigeria, rate of pre-term birth – 5 to 18% .Updated analysis -Sustainable dev. Goals 2016
  2. 4 mnths grow from disc, reach ora serrata 8 mnths & ora temporally after birth,
  3. Still no trials for determining the best level for targeted saturation.
  4. Temporal retina is susceptible to ROP. Oxygen exerts an important effect on the remodeling of the original primitive capillary network that develops in the retina
  5. Showed vasoconstriction followed by vascular occlusion.
  6. New vessels are formed from these cells..
  7. Neovsculrstn posterior to ciliary closure-long arrow,short-lens cpsule. 2) neovsculristn in surface of disc.
  8. FA of young kitten with o2 induced nv. Midtrnst phase & late phase of angiogram.
  9. Specimen from 29 week old infnt. Thickened VNGURD---vasodilatation RERGUARD..
  10. Similarly, role of Nitric oxide (Brooks and ass.) and decreased production of VEGF (Alon et al) , overall results in vasoattenuation. Mesenchyml shunt are found suggestive of pathognomic of ROP.
  11. , where retinal findings are stable. --ie, endothelial proliferation and erupt through ILM growing anteriorly .---else leads to Tractional RD.
  12. Inner zone : radius is twice the distance from disc to macul.2Peripheral of Zone I and encircles tangential to ora serrata.--Remaining temporal crest anterior to Zone II. Farthest and last zone to localize. As per 30 degree sector involvement.
  13. These extra-retinal vascularization can be : placoid, polypoid or pedunculated.Placoid being the most common. Significant synchysis and condensation of vitreous over the ridge due to depolymerisation of hyaluronic acid and collapse of collagen framework.
  14. pupil difficult to dilate because of adhesions to the anterior lens capsule and persistence of the pupillary membrane with retention of its vascular network.
  15. Posterior synechiae, iris atrophy, ectropion uveae are common formations…
  16. As defined by Cryo-ROP 1986-2003…
  17. In 2010, the Canadian Paediatric Society suggested by the Royal College of Paediatrics and Child Health, and the Royal College of Ophthalmologists-found that the risk for severe ROP was greatest in infants ≤28 weeks’ GA or weighing <1000 g at birth. 
  18. ROP takes longest to develop in very immature infants
  19. Fierson WM, American Academy of Pediatrics, Section on Ophthalmology. American Academy of Ophthalmology. American Association for Pediatric Ophthalmology and Strabismus. American Association of Certified Orthoptists Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;131(1):189–95.
  20. Leads to maturation of spindle cells which decreases gap junction between adjacent cells , decreases cytoplasmic volume of RER and thus cessation of synthesis of angiogenic factors
  21.  peripheral ablation of the avascular retina for type 1 prethreshold ROP.  monitored closely for regression of plus disease, neovascularization and ridge elevation. Lens sparing vitrectomy-ridge elevation (particularly six clock-hours or more), persistent plus disease or vitreous haze
  22. regulating VEGF signaling through VEGF receptors can restore physiologic homeostasis and permit ordered developmental intraretinal angiogenesis thereby reducing hypoxic peripheral avascular retina, which drives disordered angiogenesis.later recurrence, myopia, longer f/u
  23. essential for vascular growth through regulation of VEGF signalling…promoter of red blood cell formation, used to treat anemia in some premature infants
  24. Late-onset retinal detachment and cataracts also require aggressive management. Individuals with ROP must be followed for eye disease throughout their lives.